Cardiac Failure Clinical Trial
Official title:
Assessment of Exercise Intensity in Cardiac Rehabilitation Programmes for Patients With Chronic Heart Failure
Cardiac rehabilitation is the ideal comprehensive intervention for patients with chronic
heart failure (CHF), since it addresses the complex interplay of medical, psychological and
behavioural factors facing these individuals. Structured exercise training within a cardiac
rehabilitation programme is firmly recommended for these patients. However, it is
questionable whether patients are achieving an adequate dose of exercise to provide optimal
benefits. The essential components for setting optimal training include the appropriate
mode, duration, frequency and intensity of exercise. UK surveys of cardiac rehabilitation
describe the frequency and duration of training, but here is scant information on exercise
intensity. However, it is apparent that randomised controlled trials of exercise training
use doses more than 4 times greater than in UK current practice. The Eastbourne Exercise
Cardiology Research Group has demonstrated that although patients benefit from improved
quality of life and submaximal fitness after a hospital outpatient cardiac rehabilitation
programme, they do not achieve the increases in important prognostic indicators reported by
the majority of exercise training trials.
The critical factor in terms of eliciting a sufficient training effect while minimising risk
is the intensity of the exercise performed. It is now widely accepted that the traditional
methods of using fixed percentages of maximal heart rate or oxygen uptake to set exercise
intensity include serious errors. The European Society of Cardiology recommends that
cardiopulmonary exercise testing should be used to provide an objective evaluation of the
metabolic demand of exercise. This allows physiologically meaningful reference points to be
established for aerobic exercise prescription and is the solution to defining safe and
effective training intensities. The next step is to determine whether this information can
be transferred to a practical cardiac rehabilitation environment to set and monitor exercise
intensity
Status | Not yet recruiting |
Enrollment | 21 |
Est. completion date | April 2013 |
Est. primary completion date | April 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - Systolic heart failure with resting left ventricular ejection fraction below 40% - New York Heart Association (NYHA) class I-III - clinically stable for at least 4 weeks on optimised medication dosage according to current guidelines Exclusion criteria: - Acute coronary syndrome within past 6 months - Untreated lifethreatening cardiac arrhythmias - Acute heart failure (during initial period of haemodynamic instability) - Uncontrolled hypertension - Advanced atrioventricular block - Acute myocarditis or pericarditis - Symptomatic aortic stenosis - Severe hypertrophic obstructive cardiomyopathy - Acute systemic illness Intracardiac thrombus - Progressive worsening of exercise tolerance of dyspnoea at rest over previous 35 days - Significant ischaemia during low intensity exercise (< 2 METS, < 50W) - Uncontrolled diabetes - Recent embolism - Thrombophlebitis - New onset atrial fibrillation/flutter - > 1.8 kg increase in body mass over previous 13 days - Concurrent, continuous or intermittent dobutamine therapy - Decrease in systolic blood pressure with exercise - NYHA Functional Class IV - Complex ventricular arrhythmia at rest or appearing with exertion - Supine resting heart rate > 100 beats/min - Patient is participating in a conflicting study, is unable to perform exercise testing - Patient lacks the capacity to consent or cannot comply with study requirements |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United Kingdom | Eastbourne General Hospital | Eastbourne | East Sussex |
Lead Sponsor | Collaborator |
---|---|
Guy Lloyd |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome measure is the oxygen uptake(VO2)during exercise | 13 weeks | No | |
Secondary | Affective responses (e.g. feelings of pleasure/displeasure) | Questionnaire used to measure affective responses (Feelings Scale, Felt Anxiety Scale and Activation/Deactivation ) | 13 weeks | No |
Secondary | Weekly physical activity | Average daily physical activity: Participants' freeliving activity will be classified by ActivPAL into periods spent sitting, standing and walking, and daily energy expenditure will also be estimated from this information. | 13 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03799133 -
Safety and Efficacy of the Gastric Reactance (XL) in Patients Post-operated of Elective Cardiac Surgery
|
N/A | |
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Terminated |
NCT02205411 -
Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation
|
N/A | |
Completed |
NCT02524574 -
Tomography Positron Emission Assessment of the Impact of Cardiac Rehabilitation on Coronary Endothelial Function in Cardiac Failure
|
N/A | |
Active, not recruiting |
NCT03841084 -
Blend to Limit Oxygen in ECMO: A Randomised Controlled Registry Trial
|
Phase 2 | |
Terminated |
NCT02459054 -
Syncardia 50cc TAH-t as a Bridge to Transplant
|
N/A | |
Terminated |
NCT02859636 -
Pronostic Value of Endothelial Dysfunction in Heart Failure
|
N/A | |
Completed |
NCT04599816 -
Levosimendan Administration in Pulmonary Hypertension
|
N/A | |
Recruiting |
NCT05761639 -
Physical Exercise and Telephone Follow-up Mediated by Telerehabilitation
|
N/A | |
Not yet recruiting |
NCT04696523 -
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT03357731 -
A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function
|
Phase 2 | |
Completed |
NCT02331264 -
Cardiac Assessment of Patients With Hip Implants
|
N/A | |
Terminated |
NCT01921829 -
Protocolized Diuretic Strategy in Cardiorenal Failure
|
Phase 4 | |
Completed |
NCT06197256 -
Cardiac Dysfunction in Critically Ill Covid-19 Patients
|
||
Recruiting |
NCT03197792 -
Perioperative Portal Vein Pulsatility as a Postoperative Prognostic Indicator in Pulmonary Endarterectomy
|
N/A | |
Completed |
NCT03515980 -
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
|
Phase 1 | |
Completed |
NCT03212898 -
Pharmacist Interventions in Rural Elderly Warfarin Patients
|
N/A | |
Completed |
NCT03243604 -
cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study
|
||
Completed |
NCT06330103 -
Efficacy of AI EF Screening by Using Smartphone Application Recorded PLAX View Cardiac Ultrasound Video Clips
|
N/A | |
Completed |
NCT02660385 -
Insomnia Self-Management in Heart Failure
|
N/A |